{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-087083","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.049609+00:00","generated_at":"2026-06-12T08:49:58.984140+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Replimune enters $250M at-the-market equity agreement with Leerink, cancels prior $100M ATM","bullets":["New Sales Agreement with Leerink Partners allows sale of up to $250M of common stock via ATM or negotiated transactions.","Agent commission up to 3% of gross proceeds; Company controls timing and size of sales.","Prior $100M ATM program terminated concurrently with the new agreement.","No shares sold yet; Company may issue none under the new facility.","Registration statement on Form S-3 filed same day for the offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-087083","json":"https://secwatch.observer/filing/0001104659-23-087083.json","markdown":"https://secwatch.observer/filing/0001104659-23-087083.md","text":"https://secwatch.observer/filing/0001104659-23-087083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923087083/0001104659-23-087083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923087083/tm2317748d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:49:58.984140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50113cd2f9c4fd9ee424b169abef943d44082b76","claim":"Replimune Group, Inc. terminated 2022 Sales Agreement with Leerink Partners LLC valued at terminated (effective 2023-08-03).","evidence_excerpt":"Pursuant to the Sales Agreement, the parties mutually agreed to terminate that certain sales agreement, dated June 23, 2022, by and between the Company and the Agent (as amended, the “2022 Sales Agreement”) with respect to the Company’s previous at-the-market offering program (the “2022 ATM Program”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923087083/0001104659-23-087083-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Leerink Partners LLC"},{"label":"Value","value":"terminated"},{"label":"Effective","value":"2023-08-03"}],"fact_type":"material_agreement"},{"claim_id":"6587682a1a424679dda47ed0dfa72c5c21b65438","claim":"Replimune Group, Inc. entered into Sales Agreement with Leerink Partners LLC valued at $250,000,000 (effective 2023-08-03).","evidence_excerpt":"On August 3, 2023, Replimune Group, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (formerly known as SVB Securities LLC) (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, up to an aggregate of $250.0 million of shares of the Company’s common stock, $0.001 par value per share (the “Shares”), through the Agent, as the Company’s sales agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923087083/0001104659-23-087083-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Leerink Partners LLC"},{"label":"Value","value":"$250,000,000"},{"label":"Effective","value":"2023-08-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}